8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2021 / Double-blind randomized controlled trial
In a double-blind trial, 1961 adults with overweight or obesity without diabetes were randomly assigned (2:1) to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with lifestyle intervention. Mean body weight change was -14.9% with semaglutide compared to -2.4% with placebo (difference -12.4 percentage points; P<0.001), representing a -15.3 kg vs. -2.6 kg change. Significantly more semaglutide participants achieved weight reductions of ≥5% (86.4% vs. 31.5%), ≥10% (69.1% vs. 12.0%), and ≥15% (50.5% vs. 4.9%). Transient, mild-to-moderate nausea and diarrhea were the most common adverse events, with 4.5% of semaglutide participants discontinuing treatment due to gastrointestinal events versus 0.8% with placebo.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med, 2021. PMID 33567185
2021 / Randomized controlled trial
In a randomized trial, 78 women aged 18-40 years with PCOS received either 1000 mg resveratrol or 1000 mg placebo daily for 3 months. Compared to placebo, the resveratrol group had a significantly higher regular menstruation rate (76.47% vs. 51.61%; p = 0.03) and lower hair loss (32.10% vs. 68.00%; p = 0.009). No significant differences were found between groups for ovarian and adrenal androgens, SHBG, FAI, glycoinsulinemic metabolism, or lipid profile, and weight did not change relative to placebo.
Mansour A, Samadi M, Sanginabadi M, et al. Clin Nutr, 2021. PMID 33610422
2021 / Randomized, double-blind, parallel-group trial
A 68-week trial randomized 611 adults with overweight or obesity to once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with intensive behavioral therapy and an initial 8-week low-calorie diet. At week 68, estimated mean body weight change was -16.0% with semaglutide compared to -5.7% with placebo (difference: -10.3 percentage points, P < .001). Significantly more participants in the semaglutide group achieved weight losses of at least 5% (86.6% vs 47.6%), 10% (75.3% vs 27.0%), and 15% (55.8% vs 13.2%). Gastrointestinal adverse events occurred in 82.8% of semaglutide participants versus 63.2% with placebo, causing discontinuation in 3.4% and 0%, respectively.
Wadden TA, Bailey TS, Billings LK, et al. JAMA, 2021. PMID 33625476
2021 / Randomized, double-blind, double-dummy, placebo-controlled trial
In this 68-week trial, 1210 adults with type 2 diabetes and a BMI of at least 27 kg/m2 were randomized to receive weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo, alongside a lifestyle intervention. Estimated mean bodyweight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo (difference -6.2 percentage points, 95% CI -7.3 to -5.2; p<0.0001). Significantly more patients taking semaglutide 2.4 mg achieved at least 5% weight reduction compared to placebo (68.8% vs 28.5%; OR 4.88, 95% CI 3.58 to 6.64; p<0.0001). Adverse events, particularly gastrointestinal events, were more common with semaglutide 2.4 mg (87.6% total, 63.5% gastrointestinal) than with placebo (76.9% total, 34.3% gastrointestinal).
Davies M, Færch L, Jeppesen OK, et al. Lancet, 2021. PMID 33667417
2021 / Randomized, double-blind, phase 3a withdrawal trial
Following a 20-week run-in with subcutaneous semaglutide resulting in a mean weight loss of 10.6%, 803 participants were randomized to 48 weeks of continued semaglutide (2.4 mg/week) or placebo, both with lifestyle intervention. From week 20 to 68, participants continuing semaglutide had a mean weight change of -7.9% compared to +6.9% with placebo (difference: -14.8 percentage points, P < .001). Continued semaglutide also led to greater improvements in waist circumference (-9.7 cm), systolic blood pressure (-3.9 mm Hg), and physical functioning scores. Gastrointestinal adverse events were reported in 49.1% of semaglutide participants versus 26.1% with placebo, though discontinuation rates due to adverse events were similar (2.4% vs 2.2%).
Rubino D, Abrahamsson N, Davies M, et al. JAMA, 2021. PMID 33755728
2021 / 10-week randomized, placebo-controlled, double-blind trial
A 10-week, randomized, placebo-controlled, double-blind trial evaluated the effects of nicotinamide mononucleotide (NMN) supplementation on metabolic function in overweight or obese postmenopausal women with prediabetes. Insulin-stimulated glucose disposal, evaluated using a hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling (AKT and mTOR phosphorylation) increased after NMN supplementation but did not change after placebo. Additionally, NMN supplementation up-regulated platelet-derived growth factor receptor β and other genes involved in muscle remodeling.
Yoshino M, Yoshino J, Kayser BD, et al. Science, 2021. PMID 33888596
2021 / Double-blind, randomized, placebo-controlled trial
A double-blind, placebo-controlled trial evaluated daily supplementation with a fruit and vegetable concentrate (FVC) and high-fiber component across 57 pre-menopausal, overweight/obese female healthcare workers over five months. FVC supplementation had no effect on blood lipids, glucose, or immune parameters, but improved glucose clearance. FVC did not alter phyla-level taxonomy or alpha/beta diversity, but reduced Bacteroides abundance and increased fecal butyrate; adding a high-fiber component improved levels of health-associated bacteria.
van der Merwe M, Moore D, Hill JL, et al. Microorganisms, 2021. PMID 33920059
2020 / Single-blinded randomized pilot study
Forty participants with type 2 diabetes mellitus were randomized to 3 months of either yoga (postures and breathing exercises, n = 20) or sham yoga (nonaerobic stretching, n = 20). Both groups demonstrated significant within-group improvements in malondialdehyde, vitamin C, superoxide dismutase, fasting blood glucose, glycosylated hemoglobin, body mass index, waist circumference, and blood pressure. Yoga participants showed significantly greater improvement in reduced glutathione compared to controls, but no other significant differences between groups were observed.
Hegde SV, Adhikari P, Kotian SM, et al. Int J Yoga Therap, 2020. PMID 31283365
2020 / Randomized controlled trial
In a 12-week randomized, double-blind, placebo-controlled trial of 70 overweight adults, taking steamed onion capsules before each meal significantly decreased body fat percentage (p = 0.028) and total fat mass (p = 0.022) measured by DEXA. Computed tomography scans showed significant drops in visceral, subcutaneous, and whole fat areas at L1 and L4. Steamed onion intake also significantly reduced serum triglycerides and C-peptide levels without altering lean body mass.
Jeong S, Chae J, Lee G, et al. J Am Coll Nutr, 2020. PMID 31368861
2020 / Pre-post intervention study
An experiential education program was conducted with 30 nurse practitioners, registered nurses, and physicians who followed a whole-food plant-based (WFPB) diet for 3 weeks. Preintervention and postintervention questionnaires assessed various health and professional outcomes. Participants decreased their intake of animal-derived foods, increased WFPB food intake, lost weight, and experienced improvements in mood and energy. Additionally, perceived barriers to following and counseling about a WFPB diet declined, self-efficacy improved, and participants were likely to continue the diet and discuss it with patients.
Lessem A, Gould SM, Evans J, et al. J Am Assoc Nurse Pract, 2020. PMID 31577667
2020 / Randomized, placebo-controlled clinical trial
In a randomized, placebo-controlled trial, 40 middle-aged, obese, insulin-resistant men received 1000 mg nicotinamide riboside (NR) or placebo twice daily for 12 weeks. NR supplementation decreased NAMPT protein levels in skeletal muscle by 14%, but steady-state NAD+ levels and other biosynthetic enzymes were unchanged. NR did not affect skeletal muscle mitochondrial respiratory capacity, mitochondrial-associated protein abundance, mitochondrial fractional area, or network morphology.
Dollerup OL, Chubanava S, Agerholm M, et al. J Physiol, 2020. PMID 31710095
2020 / 3-month self-selection pilot trial
A 3-month self-selection pilot study evaluated a watermelon-focused Inflammation Management Intervention (n = 15) versus basic health education controls (n = 8). There were no group-by-time interactions for any studied outcomes. Post hoc analyses grouped participants by change in energy-adjusted Dietary Inflammatory Index (E-DII) score, noting that some intervention participants became more proinflammatory and several controls became more anti-inflammatory. Those with more anti-inflammatory dietary changes (below median E-DII change) showed differences in body fat percent (-1.27% vs +0.90%, P = .01), BMI (-0.66 vs +0.38 kg/m2, P = .06), and body weight (-0.99 vs +0.54 kg, P = .08).
Wirth MD, Shivappa N, Khan S, et al. Nutr Metab Insights, 2020. PMID 31975781
2020 / Randomized double-blind placebo-controlled pilot trial
In a 12-week pilot trial, 24 adults with obesity and mild-moderate insulin resistance were randomized to weekly oral FMT capsules from healthy lean donors or placebo for 6 weeks. There were no statistically significant improvements in insulin sensitivity between groups (+5% ± 12% in FMT vs -3% ± 32% in placebo, mean difference 9%, 95% CI -5% to 28%, p = 0.16). Additionally, no significant differences were seen for HOMA-IR (mean difference 0.2, 95% CI -0.9 to 0.9, p = 0.96), lean mass (mean difference -0.1 kg, p = 0.87), or fat mass (mean difference 1.2 kg, p = 0.18). Variable bacterial engraftment persisted throughout 12 weeks with no serious adverse events related to FMT.
Yu EW, Gao L, Stastka P, et al. PLoS Med, 2020. PMID 32150549
2020 / Randomized, double-blinded, placebo-controlled, crossover trial
In a randomized, double-blinded, placebo-controlled crossover study, 13 healthy overweight or obese adults received 1000 mg/d nicotinamide riboside (NR) and placebo for 6 weeks each. NR increased skeletal muscle markers of NAD+ synthesis, body fat-free mass (62.65% ± 2.49% vs 61.32% ± 2.58%; change: 1.34% ± 0.50%, P = 0.02), and sleeping metabolic rate. Skeletal muscle acetylcarnitine concentrations increased (4558 ± 749 vs 3025 ± 316 pmol/mg dry weight; change: 1533 ± 683, P = 0.04), along with exercise acetylcarnitine-forming capacity (P = 0.01). However, NR had no effects on insulin sensitivity, mitochondrial function, hepatic/intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, blood pressure, inflammation markers, or energy metabolism.
Remie CME, Roumans KHM, Moonen MPB, et al. Am J Clin Nutr, 2020. PMID 32320006
2020 / Randomized controlled intervention study
In Slovenia during winter, 105 healthy adults with suboptimal vitamin D status (25-OH-VitD 30-50 nmol/L) were randomized to three daily cholecalciferol formulations (1000 IU/25 µg as capsules, oil-based spray, or water-based spray) or a control group for two months. Supplementation significantly increased serum 25-OH-VitD levels compared to control (pooled Δc 32.8 nmol/L; 95% CI: 23.0, 42.5, p < 0.0001), with no significant differences between the formulations. Supplementation efficiency was associated with body mass index and baseline 25-OH-VitD, showing higher efficiency in participants with BMI < 25 and those with more pronounced insufficiency. The tested dosage was not sufficient to reach recommended levels in all subjects.
Žmitek K, Hribar M, Hristov H, et al. Nutrients, 2020. PMID 32365732
2020 / Two-period randomized crossover trial
In a randomized crossover trial, 55 adults with elevated BMI and cardiometabolic risk consumed 3/4 cup/day of mixed dried fruits (plums, figs, dates, raisins) or an isocaloric, carbohydrate-matched control snack for 4 weeks. Lipid and lipoprotein concentrations did not differ between conditions, though dried fruit increased LDL-cholesterol from baseline (0.10 mmol/l, 95% CI 0.01, 0.20). Compared with control, dried fruit increased mean fasting glucose (0.08 mmol/l, 95% CI 0.005, 0.16; P = 0.038), while vascular outcomes, fasting insulin, and C-reactive protein did not differ. Mean weight changes did not differ between groups (P = 0.55), but tended to increase in both.
Sullivan VK, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 32513313
2020 / Randomized crossover trial
In the SWAP-MEAT crossover trial, 36 healthy adults consumed ≥2 servings/day of plant-based alternative meat versus animal meat for 8 weeks each with no washout period. Overall mean ± SEM TMAO concentrations were lower during the plant phase (2.7 ± 0.3 vs. 4.7 ± 0.9 µM, P = 0.012), though a significant order effect occurred; TMAO was significantly lower only in participants receiving plant meat second. LDL-cholesterol concentrations (109.9 ± 4.5 vs. 120.7 ± 4.5 mg/dL, P = 0.002) and body weight (78.7 ± 3.0 vs. 79.6 ± 3.0 kg, P < 0.001) were also significantly lower during the plant-based phase.
Crimarco A, Springfield S, Petlura C, et al. Am J Clin Nutr, 2020. PMID 32780794
2020 / Multicenter, randomized, double-blind, placebo-controlled trial
One hundred menopausal Korean women were randomly assigned to receive either 400 mg/day of porcine placental extract (PPE) or a placebo for 12 weeks. While the Kupperman Index (KMI) decreased in both groups, the overall difference between groups was not statistically significant. However, KMI decreased significantly more with PPE than placebo in women with BMI 23 kg/m2 or higher (-18.52 ± 9.09 vs -11.40 ± 10.68, P < 0.05) and in early menopausal women (-17.29 ± 9.07 vs -11.29 ± 10.68, P < 0.05). Estradiol levels also increased significantly in the PPE group at 12 weeks (11.13 ± 35.13 pg/m, P < 0.05).
Lee JY, Lee C, Yoon SH, et al. Taiwan J Obstet Gynecol, 2020. PMID 32917317
2020 / Randomized, placebo-controlled study
Participants were randomized to wear a novel nasal device for 5-12 hours daily or receive daily saline nasal drops, alongside a 500 kcal/day reduced diet for 12 weeks. Sense of smell decreased from 6.4 ± 0.9 to 4.4 ± 1.5 in the device group (p < 0.001) with no change in controls. Overall weight loss was 6.6 ± 3.7% in the device group versus 5.7 ± 3.5% in controls (between-group p > 0.05), but was significantly greater with the device among participants aged ≤50 years (7.7 ± 4.2% vs. 4.1 ± 2.9%, p = 0.02). The device group also showed significant reductions in insulin, HOMA-IR, and preferences for sugar, sweet beverages, and artificial sweeteners.
Dicker D, Beck A, Markel A, et al. Obes Facts, 2020. PMID 32950989
2019 / Three experimental studies (laboratory and field)
Three studies examined the effect of a justification cue (license condition) versus no cue (control condition) on caloric consumption. In Studies 1 (N = 85) and 2 (N = 95), participants could eat freely from unhealthy snacks, while in Study 3 (N = 110), participants chose a snack at a take-out lunch place. Across all studies, caloric consumption was higher in the license condition compared to the control condition, with participants eating more unhealthy snacks in Studies 1 and 2 and choosing higher-calorie snacks in Study 3.
Prinsen S, Evers C, de Ridder DTD Psychol Health, 2019. PMID 30422003
2019 / Three-group randomized crossover trial
Researchers evaluated the acute effects of two energy- and macronutrient-matched meals—a vegan meal with tofu (V-meal) versus a processed-meat and cheese meal (M-meal)—in men with type 2 diabetes, obese men, and healthy men (n=20 each). Postprandial GLP-1 secretion increased after the V-meal in diabetic men (by 30.5%) and healthy men (by 15.8%), while amylin increased across all groups (diabetic by 15.7%, obese by 11.5%, healthy by 13.8%). Postprandial PYY increased significantly only in healthy men (by 18.9%). Satiety was higher after the V-meal in all groups: by 9% in diabetic, 18.7% in obese, and 25% in healthy men.
Klementova M, Thieme L, Haluzik M, et al. Nutrients, 2019. PMID 30642053
2019 / Single-blinded randomized controlled trial
In a 12-week single-blinded trial, 77 constipated patients with type 2 diabetes received cookies containing 10 g flaxseed, 10 g psyllium, or placebo twice daily. Compared to placebo, both flaxseed and psyllium groups showed significant improvements from baseline in constipation symptoms (P = 0.002), stool consistency (P < 0.001), weight (P < 0.001), BMI (P < 0.001), fasting plasma glucose (P = 0.004), cholesterol (P = 0.010), LDL cholesterol (P = 0.031), and cholesterol/HDL cholesterol ratio (P = 0.019). Flaxseed appeared superior to psyllium for improving these markers, and no adverse effects were observed.
Soltanian N, Janghorbani M Clin Nutr ESPEN, 2019. PMID 30661699
2019 / Randomized controlled crossover trial
Twenty-four overweight men completed a randomized crossover trial evaluating extruded sorghum versus extruded wheat during two 8-week periods with a 4-week washout. Sorghum intake reduced body fat percentage and raised daily intakes of carbohydrate and dietary fiber compared with wheat. Serum glutathione peroxidase concentration increased with sorghum, but this change did not differ significantly from wheat.
Anunciação PC, Cardoso LM, Alfenas RCG, et al. Food Res Int, 2019. PMID 30884705
2019 / Cluster randomized controlled trial
A cluster randomized trial evaluated an 8-module workplace wellness program led by dietitians across 160 worksites (20 intervention sites with 4,037 employees and 140 control sites with 28,937 employees). After 18 months, intervention participants reported higher rates of engaging in regular exercise (69.8% vs 61.9%; adjusted difference, 8.3 percentage points) and actively managing weight (69.2% vs 54.7%; adjusted difference, 13.6 percentage points). However, there were no significant effects on 27 other self-reported outcomes (including food choices), 10 clinical markers (including cholesterol, blood pressure, and BMI), 38 health spending/utilization metrics, or 3 employment outcomes.
Song Z, Baicker K JAMA, 2019. PMID 30990549